Targeting the immunoproteasome and VCP/p97 in autoimmune disorders and viral infection
M del Río Oliva - 2022 - kops.uni-konstanz.de
The proteasome is a multicatalytic system involved in the degradation of polyubiquitinated
proteins. Thus, the proteasome is key to maintaining cell homeostasis. Stress and pro …
proteins. Thus, the proteasome is key to maintaining cell homeostasis. Stress and pro …
[PDF][PDF] The immunoproteasome: a novel drug target for autoimmune diseases
The immunoproteasome, a special class of the proteasome, is mainly expressed in cells of
haematopoietic origin. Additionally, during inflammation, the immunoproteasome is induced …
haematopoietic origin. Additionally, during inflammation, the immunoproteasome is induced …
Targeting the Immunoproteasome in Health and Disease
S Mundt - 2016 - kops.uni-konstanz.de
The proteasome is a multicatalytic enzyme expressed in all eukaryotic cells and responsible
for the degradation of polyubiquitinated proteins. Thereby, the proteasome regulates protein …
for the degradation of polyubiquitinated proteins. Thereby, the proteasome regulates protein …
Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome
M del Rio Oliva, CJ Kirk, M Groettrup… - European Journal of …, 2022 - Wiley Online Library
Polymyositis (PM) is a chronic autoimmune inflammatory myopathy resulting in muscle
weakness. The limited approved therapies and their poor efficacy contribute to its …
weakness. The limited approved therapies and their poor efficacy contribute to its …
[HTML][HTML] On the role of the immunoproteasome in protein homeostasis
M Basler, M Groettrup - Cells, 2021 - mdpi.com
Numerous cellular processes are controlled by the proteasome, a multicatalytic protease in
the cytosol and nucleus of all eukaryotic cells, through regulated protein degradation. The …
the cytosol and nucleus of all eukaryotic cells, through regulated protein degradation. The …
Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity
M Basler, MM Lindstrom, JJ LaStant, JM Bradshaw… - EMBO …, 2018 - embopress.org
Cells of hematopoietic origin express high levels of the immunoproteasome, a cytokine‐
inducible proteasome variant comprising the proteolytic subunits LMP2 (β1i), MECL‐1 (β2i) …
inducible proteasome variant comprising the proteolytic subunits LMP2 (β1i), MECL‐1 (β2i) …
The Effect of Immunoproteasome Inhibition on T Helper Cells in Acute Inflammation
F Oliveri - 2022 - kops.uni-konstanz.de
The immunoproteasome is a variant of the 26S proteasome in which the catalytically active
standard β-subunits (β1c, β2c and β5c) are replaced by low molecular mass polypeptide …
standard β-subunits (β1c, β2c and β5c) are replaced by low molecular mass polypeptide …
The immunoproteasome in antigen processing and other immunological functions
M Basler, CJ Kirk, M Groettrup - Current opinion in immunology, 2013 - Elsevier
Treatment of cells with interferon-γ leads to the replacement of the constitutive catalytic
proteasome subunits β1, β2, and β5 by the inducible subunits LMP2 (β1i), MECL-1 (β2i) …
proteasome subunits β1, β2, and β5 by the inducible subunits LMP2 (β1i), MECL-1 (β2i) …
Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome
Background and Purpose Multicatalytic endopeptidase complex‐like‐1 (β2i), low molecular
mass polypeptide (LMP) 2 (β1i) and LMP7 (β5i) are the proteolytically active subunits of the …
mass polypeptide (LMP) 2 (β1i) and LMP7 (β5i) are the proteolytically active subunits of the …
[HTML][HTML] Immunoproteasome inhibition attenuates experimental psoriasis
Introduction Psoriasis is an autoimmune skin disease associated with multiple comorbidities.
The immunoproteasome is a special form of the proteasome expressed in cells of …
The immunoproteasome is a special form of the proteasome expressed in cells of …